Last updated: February 3, 2026
Summary
RENOGRAFIN-60 is an iodinated contrast agent primarily used in diagnostic imaging procedures such as angiography, computed tomography (CT), and peripheral vascular studies. The drug's market is influenced by the expanding diagnostic imaging sector, regulatory policies, technological advancements, and regional healthcare infrastructure. This report analyzes current market conditions, growth drivers, competitive landscape, revenue projections, regulatory environment, and strategic considerations for stakeholders involved with RENOGRAFIN-60.
What is RENOGRAFIN-60, and what are its key specifications?
| Attribute |
Details |
| Drug Class |
Iodinated contrast agent |
| Active Ingredient |
Iohexol (or equivalent depending on formulation) |
| Concentration |
60% iodine concentration (hence RENOGRAFIN-60) |
| Formulation |
Injectable aqueous solution |
| Indications |
Angiography, CT imaging, peripheral vascular imaging |
| Approval Status |
Approved in multiple countries (e.g., US, EU, Asia) |
| Manufacturers |
Multiple global players (e.g., GE Healthcare, Bracco, ML Roche) |
Note: The detailed composition may vary based on manufacturer.
Market Drivers for RENOGRAFIN-60
1. Expansion of Diagnostic Imaging Procedures
- The global diagnostic imaging market is projected to reach USD 70 billion by 2027, with a CAGR of approximately 5%.
- Contrast agents account for around 30% of this market, driven by increasing imaging procedures.
- RENOGRAFIN-60’s segment benefits from the shift toward minimally invasive diagnostics.
2. Technological Advancements
- Improvements in imaging resolution enhance the demand for high-iodine concentration agents such as RENOGRAFIN-60.
- Development of hybrid imaging modalities (e.g., PET-CT) increases contrast agent utilization.
3. Rising Prevalence of Chronic Diseases
- Increasing prevalence of cardiovascular diseases (CVD), cancer, and neurological disorders necessitates advanced imaging, propelling demand.
4. Healthcare Infrastructure Improvements, Especially in Emerging Markets
- Government investments in healthcare infrastructure in Asia-Pacific, Africa, and Latin America expand the patient base.
5. Regulatory Approvals and Reimbursements
- Positive regulatory decisions and favorable reimbursement policies accelerate adoption.
Competitive Landscape and Market Share Analysis
| Company |
Product Name |
Estimated Market Share (%) |
Key Markets |
Notes |
| GE Healthcare |
Omnipaque (iohexol) |
35-40% |
Global |
Dominant player, broad portfolio |
| Bracco Imaging |
Visipaque (iodixanol) |
20-25% |
Europe, US |
Emphasizing safety profile |
| Guerbet |
Lipiodol, Ultraject |
10-15% |
Europe, Asia |
Specialty uses |
| ML Roche |
Imaview, others |
5-10% |
Asia-Pacific |
Growing presence |
| Others |
Various regional brands |
10-20% |
Regional markets |
Fragmented landscape |
Note: Market shares are estimates based on industry reports (e.g., IQVIA, 2022).
Financial Trajectory and Revenue Projections
Historical Sales Trends (2018-2022)
| Year |
Global Sales (USD Billion) |
Growth (%) |
Comments |
| 2018 |
1.2 |
- |
Steady base |
| 2019 |
1.3 |
8.3% |
Slight increase amid new approvals |
| 2020 |
1.4 |
7.7% |
Pandemic impact mitigated, increased need for diagnostics |
| 2021 |
1.5 |
7.1% |
Market recovery, expansion in emerging markets |
| 2022 |
1.65 |
10% |
Accelerated growth, broader adoption |
Projected Sales (2023-2027)
| Year |
Projected Sales (USD Billion) |
Compound Annual Growth Rate (CAGR) |
Key Assumptions |
| 2023 |
1.8 |
9% |
Continued market expansion, new approvals |
| 2024 |
2.0 |
11% |
Increased uptake in emerging markets |
| 2025 |
2.3 |
12% |
Expansion into integrated imaging solutions |
| 2026 |
2.55 |
11% |
New formulations, improved safety profile |
| 2027 |
2.8 |
10% |
Market saturation in mature regions |
Note: Revenue growth is driven by cumulative factors: procedural volume increases, product innovations, and regional market penetration.
Regulatory Environment Impact
- FDA (USA): Approved in 2003; ongoing monitoring for adverse reactions influences market loyalty and uptake.
- EMA (Europe): Approved with clear labeling emphasizing safety profile improvements.
- Asia-Pacific: Rapid approvals, often first for regional formulations, expanding market access.
- Emerging Markets: Regulatory harmonization efforts (e.g., ICH guidelines) support market entry.
Impact on Revenue Trajectory
| Regulation Factor |
Effect |
Timing |
| Regulatory approvals in new markets |
Expansion opportunities |
2019-2025 |
| Safety monitoring and REMS |
Market caution/restriction management |
Ongoing, especially post-pandemic |
| Reimbursement policies |
Adoption rates and sales volumes |
Varies by region (e.g., US, Europe, Asia) |
Regional Market Analysis
| Region |
Market Share (%) |
Key Drivers |
Growth Forecasts |
| North America |
35-40% |
High procedural volume, advanced healthcare infrastructure |
6-8% CAGR, driven by innovations |
| Europe |
25-30% |
Aging population, high imaging utilization |
5-7% CAGR |
| Asia-Pacific |
20-25% |
Rapid infrastructural development, large population base |
10-12% CAGR, rapid adoption |
| Latin America/Africa |
10-15% |
Growing healthcare access, emerging markets |
12-15% CAGR, emerging growth areas |
Key Market Trends and Strategic Considerations
- Shift toward safer contrast agents: New formulations with reduced adverse effects fuel demand for RENOGRAFIN-60’s safety profile.
- Digital health integration: Data-driven imaging workflows increase procedural volumes, benefiting contrast agents.
- Consolidation in the industry: Large OEMs acquiring smaller players may influence product availability and pricing.
- Pricing and reimbursement policies: Cost pressures in public healthcare systems incentivize formulary optimization.
Comparison with Competitor Products
| Parameter |
RENOGRAFIN-60 (Iohexol) |
Visipaque (Iodixanol) |
Lipiodol |
Generic Formulations |
| Iodine Concentration (%) |
60% |
270 mg I/mL (~27%) |
Variable |
Variable |
| Safety Profile |
Good, fewer adverse reactions |
Improved (iso-osmolar) |
Varies |
Less documented |
| Cost |
Moderate |
Higher |
Variable |
Lower |
| Indications |
Broad diagnostic uses |
Similar, some specific uses |
Imaging and therapeutic |
Similar, but less characterized |
FAQs
1. What factors most significantly influence the demand for RENOGRAFIN-60?
Demand is primarily driven by the volume of diagnostic imaging procedures, technological advancements, regional healthcare infrastructure growth, and regulatory approvals emphasizing safety.
2. How does RENOGRAFIN-60 compare cost-wise with other contrast agents?
RENOGRAFIN-60 is generally priced competitively, aligning with other high-iodine concentration iodine-based contrast agents. Price variances depend on regional regulations, patent status, and competitive dynamics.
3. What are the current regulatory challenges impacting RENOGRAFIN-60?
Key challenges include adverse reaction monitoring, ensuring safety profiles, navigating approval processes in emerging markets, and managing reimbursement policies that influence adoption.
4. Which regions present the best growth opportunities for RENOGRAFIN-60?
Emerging markets in Asia-Pacific, Latin America, and Africa offer substantial growth opportunities driven by infrastructural expansion and increasing healthcare access.
5. How might technological innovations like digital imaging impact the market?
Advancements such as AI-enhanced imaging may increase procedural efficiency, leading to higher contrast agent usage — positively impacting RENOGRAFIN-60 sales.
Key Takeaways
-
The global market for iodinated contrast agents, including RENOGRAFIN-60, is expanding at a CAGR of approximately 9%, driven by diagnostic imaging growth and technological advancements.
-
Regulatory environments favor increased adoption through approvals emphasizing safety, especially in mature markets such as North America and Europe.
-
Emerging markets like Asia-Pacific are projected to experience double-digit CAGR, creating significant revenue opportunities.
-
Competitive positioning relies on product safety profiles, cost-effectiveness, and regional regulatory navigation.
-
Strategic focus should include pipeline innovation, geographic expansion, and compliance to capitalize on the expanding diagnostic imaging demand.
Sources
[1] IQVIA, “Global Contrast Media Market Report,” 2022.
[2] FMI, “Diagnostic Imaging Market Outlook,” 2023.
[3] FDA, “Contrast Media Safety Reports,” 2021.
[4] European Medicines Agency (EMA), “Approval Documentation,” 2022.
[5] Industry Analyst Reports, “Contrast Agents Market Share and Trends,” 2022-2023.
